Safety and tolerability of slow-release oral morphine versus methadone in the treatment of opioid dependence
Standard
Safety and tolerability of slow-release oral morphine versus methadone in the treatment of opioid dependence. / Hämmig, Robert; Köhler, Wilfried; Bonorden-Kleij, Karin; Weber, Bernd; Lebentrau, Karin; Berthel, Toni; Babic-Hohnjec, Lucija; Vollmert, Christian; Höpner, Doris; Gholami, Najibulah; Verthein, Uwe; Haasen, Christian; Reimer, Jens; Ruckes, Christian.
In: J SUBST ABUSE TREAT, Vol. 47, No. 4, 01.10.2014, p. 275-281.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Safety and tolerability of slow-release oral morphine versus methadone in the treatment of opioid dependence
AU - Hämmig, Robert
AU - Köhler, Wilfried
AU - Bonorden-Kleij, Karin
AU - Weber, Bernd
AU - Lebentrau, Karin
AU - Berthel, Toni
AU - Babic-Hohnjec, Lucija
AU - Vollmert, Christian
AU - Höpner, Doris
AU - Gholami, Najibulah
AU - Verthein, Uwe
AU - Haasen, Christian
AU - Reimer, Jens
AU - Ruckes, Christian
N1 - Copyright © 2014 Elsevier Inc. All rights reserved.
PY - 2014/10/1
Y1 - 2014/10/1
N2 - Opioid substitution treatment (OST) for opioid dependence may be limited by adverse events (AEs). Increasing the range of therapeutic options optimizes outcomes and facilitates patient management. An international, multi-center, two-phase study investigated the efficacy and safety of slow-release oral morphine (SROM) versus methadone in patients receiving methadone therapy for opioid dependence. In phase 1 (two way cross-over, 11 weeks each period) patients were randomized to SROM or methadone oral solution. In phase 2 (25 weeks), patients continued treatment with SROM (group A) or switched from methadone to SROM (group B). In total, 211 out of 276 completed phase 1 and 198 entered phase 2 (n=95 group A, n=103 group B). Treatment with both SROM and methadone was well tolerated. However, the mean QTc-interval associated with methadone was significantly longer than that under SROM. Higher treatment satisfaction, fewer cravings for heroin, and lower mental stress were reported with SROM. This study adds a significant further weight of evidence that SROM is an effective and well tolerated long-term maintenance treatment for opioid dependence with a beneficial risk profile compared to methadone regarding cardiac effects and supports its clinical utility.
AB - Opioid substitution treatment (OST) for opioid dependence may be limited by adverse events (AEs). Increasing the range of therapeutic options optimizes outcomes and facilitates patient management. An international, multi-center, two-phase study investigated the efficacy and safety of slow-release oral morphine (SROM) versus methadone in patients receiving methadone therapy for opioid dependence. In phase 1 (two way cross-over, 11 weeks each period) patients were randomized to SROM or methadone oral solution. In phase 2 (25 weeks), patients continued treatment with SROM (group A) or switched from methadone to SROM (group B). In total, 211 out of 276 completed phase 1 and 198 entered phase 2 (n=95 group A, n=103 group B). Treatment with both SROM and methadone was well tolerated. However, the mean QTc-interval associated with methadone was significantly longer than that under SROM. Higher treatment satisfaction, fewer cravings for heroin, and lower mental stress were reported with SROM. This study adds a significant further weight of evidence that SROM is an effective and well tolerated long-term maintenance treatment for opioid dependence with a beneficial risk profile compared to methadone regarding cardiac effects and supports its clinical utility.
U2 - 10.1016/j.jsat.2014.05.012
DO - 10.1016/j.jsat.2014.05.012
M3 - SCORING: Journal article
C2 - 25064422
VL - 47
SP - 275
EP - 281
JO - J SUBST ABUSE TREAT
JF - J SUBST ABUSE TREAT
SN - 0740-5472
IS - 4
ER -
